Trial reportPsychopharmacology2006
Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment.
Trial report in Psychopharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Pharmacotherapy for post traumatic stress disorder (PTSD).The Cochrane database of systematic reviews · 2022Pooled it
- Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.Progress in neuro-psychopharmacology & biological psychiatry · 2009Pooled it
- Involvement of the GABAergic system in PTSD and its therapeutic significance.Frontiers in molecular neuroscience · 2023Review
- Regional specificity and clinical correlates of cortical GABA alterations in posttraumatic stress disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Protocol for individual participant data meta-analysis of interventions for post-traumatic stress.BMJ open · 2022Article
- Sex, Pramipexole and Tiagabine Affect Behavioral and Hormonal Response to Traumatic Stress in a Mouse Model of PTSD.Frontiers in pharmacology · 2021Article
- Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.Biological psychiatry · 2019Review
- Impact of Traumatic Stress on Sleep and Management Options in Women.Sleep medicine clinics · 2018Review
- Relations Between Resilience, Positive and Negative Emotionality, and Symptoms of Anxiety and Depression.Psychological trauma : theory, research, practice and policy · 2014Article
- Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.BMC psychiatry · 2014Review
- Targeting memory processes with drugs to prevent or cure PTSD.Expert opinion on investigational drugs · 2012Review
- Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence.Neuropharmacology · 2012Review
- Pharmacotherapy of PTSD: premises, principles, and priorities.Brain research · 2009Review
- The GABA transporter 1 (SLC6A1): a novel candidate gene for anxiety disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2009Article
- Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder.Molecular psychiatry · 2008Article
- Antiepileptic drugs for the treatment of post-traumatic stress disorder.Current psychiatry reports · 2007Review
- Glutamate and anxiety disorders.Current psychiatry reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePreliminary results suggest a potential benefit of agents that enhance gamma-aminobutyric acid (GABA) neurotransmission in treating posttraumatic stress disorder (PTSD).
objectivesIt is the aim of this study to evaluate the effect of a selective GABA reuptake inhibitor (SGRI), tiagabine, in patients with PTSD.
methodsTwenty-nine adult outpatients with PTSD were treated with open-label tiagabine for 12 weeks. Those who responded to treatment (i.e., demonstrated at least minimal clinical improvement) were randomly assigned to double-blind treatment with either tiagabine or matching placebo. Efficacy assessments included measures of PTSD, anxiety, depression, sleep quality, resilience, and disability. Safety evaluation included changes in vital signs and weight and treatment-emergent adverse events.
resultsIn subjects completing open-label treatment (n=19), significant improvement was observed on all outcome measures (P<0.05) and the treatment was well tolerated. Eighteen subjects responded and were randomized into the double-blind phase. Following randomization, benefits of treatment were generally upheld, but there was no greater incidence of relapse in the placebo group. However, continued treatment with tiagabine was associated with a greater trend toward likelihood of remission than if one was switched to placebo (P<0.08).
conclusionsThese findings suggest a possible role for the SGRI tiagabine in the treatment of PTSD. As the role of GABAergic drugs in PTSD is poorly defined, larger, randomized, double-blind, placebo-controlled trials are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.